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Abstract
Background: Type 2 diabetes poses an increasing healthcare burden in Japan. Although insulin treatment has
diversified in recent years, the literature on the utilization of healthcare services among patients with type 2 diabetes
undergoing different insulin therapy regimens is scarce. The current study aimed to characterize the real-world insulin
treatment patterns and associated utilization of healthcare services among patients with type 2 diabetes who initiated
insulin therapy during the study period.
Methods: We examined data from a hospital-based database consisting of administrative and laboratory data from
121 acute-phase hospitals throughout Japan from April 2008 to August 2012. Patients diagnosed with type 2 diabetes
and receiving continuous insulin therapy, defined by three insulin claims or more, were included in the analysis.
Results: Of the 2,145 insulin initiators, at initiation 46.5 % received rapid-acting insulin alone, 36.6 % received an
intensive regimen, 11.4 % received long-acting insulin alone, and 5.5 % received pre-mixed insulin alone. Patients
treated with rapid-acting insulin alone were older, experienced more comorbid conditions, had lower HbA1c, and
more often had initiated their insulin treatment at inpatient admission, compared to patients treated with other types
of insulin. Inpatient admission was more common and longer for patients taking rapid-acting insulin and an intensive
regimen than those taking long-acting or pre-mixed insulin, and most were readmitted within 1 year. Utilization of
outpatient clinics was approximately once per month, and emergency department visits were observed to be rare.
Conclusions: This retrospective observational descriptive study found varied treatment and healthcare service
utilization patterns, as well as disparities in patient characteristics across insulin regimens. Future research should assess
the basis for these various utilization patterns associated with insulin to conduct robust analyses of clinical and
economic outcomes.
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Background
Diabetes poses a significant and increasing healthcare
burden. The Japanese Ministry of Health, Labour and
Welfare conducted the National Health and Nutrition
Survey in 2012 and found that nearly one quarter of in-
dividuals were either diabetic or prediabetic (11.4 % for
diabetes and 12.7 % for prediabetes) [1]. It is estimated
that 9.5 million individuals in Japan had type 2 diabetes
mellitus (T2DM) in 2012 [1], a gradual increase from 8.9
million in 2007 [2]. Recently, more individuals sought
treatment for their diabetes, with 2.7 million1 diagnosed
patients visiting a clinic or hospital for diabetes in 2011
compared to an estimated 2.1 million in 1999 [3].
The increasing prevalence of diabetes and the growing
number of patients receiving treatment represents a sig-
nificant economic burden. The total healthcare expend-
iture for diabetes was 1,209 billion JPY—4.3 % of the
total healthcare expenditure in 2012 [4]. Just as preva-
lence rates have increased steadily, the overall healthcare
expenditure on diabetes has been rising, with an increase
of nearly 100 billion JPY from 2005 to 2012, from 1,117
billion JPY to 1,209 billion JPY [4, 5].
Alongside the increases in prevalence and cost, insulin
treatment has diversified in recent years. With respect to
initiation and adjustment of insulin, the Japan Diabetes
Society (JDS) treatment guideline [6] recommends diet
and exercise therapies as the first step in treating
T2DM, followed by one type of oral hypoglycemic agent
or insulin in small doses and then combination therapy,
should the preceding steps be unsuccessful [6]. Various
factors including patients’ age, level of obesity, the state
of liver and kidney function, insulin secretory capacity,
and the degree of insulin resistance should be deter-
mined prior to starting pharmacological treatment [6].
Previous studies reveal the use of different types and
combinations of insulin for diabetes treatment [7], as
well as a diverse role of insulin in different settings for a
variety of patients with diabetes mellitus [8]. Today, pa-
tients can initiate their insulin therapy in more personal-
ized, patient-tailored manners, ranging from long-acting
insulin only to supplementing with oral hypoglycemic
agents to a combination of rapid- and long-acting insu-
lin for an intensive regimen [9].
Despite a large number of studies on T2DM, little in-
formation exists on the real-world treatment patterns
and on the associated healthcare service use among
Japanese insulin initiators. By examining an administra-
tive hospital database containing electronic health re-
cords from acute-phase hospitals throughout Japan, the
current study aimed to characterize the real-world
utilization patterns of healthcare services for patients
with T2DM on different types of insulin therapy
regimens over the 1-year period following initiation of
insulin therapy.
Methods
Data sources and data collection
An automated hospital-based database obtained from
hospital electronic information systems, developed by
Medical Data Vision Co., Ltd (MDV), was utilized. The
database contained administrative and laboratory data
from 121 acute-phase hospitals throughout Japan,
among which 25 had less than 200 beds, 75 had between
200 and 499 beds, and 21 had 500 beds or more. This
anonymous database had similar age and gender distri-
bution to that of national patient statistics [3] and in-
cluded information on drug prescriptions, medical
procedures, surgeries, laboratory results such as HbA1c,
diagnosis codes, age, gender, date of medical service, de-
partment, and inpatient/outpatient status [10]. Although
HbA1c was reported with the JDS system in the data-
base because it was widely used in Japan at the time of
data collection, all HbA1c values in the current study
were converted to the National Glycohemoglobin
Standardization Program (NGSP) system with the for-
mula recommended by JDS (NGSP = JDS + 0.4 [11]).
Data collected between April 1, 2008, and August 31,
2012, were analyzed. The closest value to their index
date was used as their baseline HbA1c value.
Population
Patients were included in the study based on the follow-
ing criteria: 1) diagnosed with T2DM, identified with the
International Classification of Disease 10th revision
(ICD-10) codes of E11 (non-insulin dependent diabetes
mellitus), E12 (malnutrition-related diabetes mellitus), or
E14 (unspecified diabetes mellitus), with no codes for
E10 (type 1 diabetes mellitus); 2) received insulin, identi-
fied using ICD-10 code Z79.4 and drug codes (Add-
itional file 1: Table S1); and 3) were at least 18 years old
when they first received insulin. It was also required that
patients had at least 18 months of data because insulin-
naïve patients were identified by having no record of in-
sulin claim during the 6-month period prior to their first
insulin claim (=index date) and the 1-year post index
period was used for the analysis. In addition, patients
who did not have three or more insulin claims during
the 1-year post index period, as well as patients who
were inpatients on their index date without one or more
insulin claims after discharge, were excluded. To ensure
we had true insulin initiators, patients with a small num-
ber of insulin claims were excluded because they may
have already been receiving most of their care at a hos-
pital not included in the database and it was possible
that they only visited a hospital in this database for acute
treatment and received insulin during their inpatient
stay. Because the database did not track patients outside
of the hospitals included, strict criteria were used to
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limit the number of misclassifications, which also limited
the effective sample size for analyses.
Insulin treatments were classified into the following
four groups based on the types and intensity of therapy
prescribed over the 1-year post index period: long-acting
insulin, rapid-acting insulin, pre-mixed insulin, and in-
tensive regimen groups. The long-acting group included
patients who received long acting insulin (e.g., insulin
glargine, insulin detemir) or intermediate-acting insulin
(e.g., isophane) and did not have a claim for any other
types of insulin for 100 days after their long-acting insu-
lin claim. The 100-day gap was used because patients
can be provided up to 90 days of insulin at one time.
The rapid-acting insulin group included patients who re-
ceived rapid-acting insulin (e.g., lispro, aspart, gulisine)
or regular insulin (e.g., insulin neutral [regular]) and did
not have a claim for any other types of insulin for
100 days after their rapid-acting insulin claim. The pre-
mixed insulin group included patients who received a
prepared combination of rapid- and long-acting insulin
and did not have a claim for any other types of insulin
for 100 days after their pre-mixed insulin claim. The in-
tensive regimen group included patients who received a
combination of rapid-acting, long-acting, and/or pre-
mixed insulin. If patients had claims for multiple types
of insulin during the 1-year post index period and if the
number of days between the two adjacent claims was
less than 100 days, an assumption was made that these
patients belonged to the intensive regimen group. On
the other hand, if the adjacent claims were for different
types of insulin and if they were prescribed with a gap of
100 days or more between them, an assumption was
made that these patients first initiated with one type of
insulin and later switched to another type of insulin.
Patients with gaps of more than 100 days were consid-
ered to be intermittent users if they used insulin again at
a later date or were considered dropped out if no further
claims for insulin were found.
Statistical analysis
Descriptive analyses were performed on the study popu-
lation for patient characteristics, treatment patterns, and
healthcare service utilization. Continuous variables were
described by presenting the mean, standard deviation,
median, minimum, and maximum. Categorical variables
were described by presenting the number and percent-
age of patients in each category. If HbA1c was not mea-
sured at index, the closest HbA1c value prior to the
index date was used for the blood glucose analyses. Data
reduction and descriptive statistics were performed using
SAS software version 9.1.
Ethics statement
The study was approved by the Ethics Committee of the
International University of Health and Welfare (#12-190).
Results
Selected patients
Sample selection and attrition are detailed in Fig. 1. Of
90,808 patients with diabetes mellitus visiting the hospi-
tals in the database between April 1, 2008, and August
31, 2012, a total of 81,318 were at least 18 years old and
Fig. 1 Patient selection chart
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had a diagnosis of T2DM. Of 6,650 patients who had
data for both the 6-month pre-index period required to
determine previous treatment history and the 1-year
post-index period required for the analysis, 2,145 pa-
tients were determined to be insulin initiators who re-
ceived most of care at the hospitals in the database and
included in the analysis. To reduce misclassification of
patients, patients who did not have three or more insulin
claims during the 1-year post index period were
excluded.
Insulin regimen at initiation
Of the 2,145 patients who initiated and continued insu-
lin therapy, more than half (63.4 %; N= 1,359) were re-
ceived a simple regimen with one type of insulin (rapid-
acting, pre-mixed, or long-acting insulin only), whereas
the remainder (36.6 %; N= 786) received a combination
of multiple insulin types (an intensive regimen). Ap-
proximately half of patients were in the rapid-acting in-
sulin group (46.5 %; N= 997), and fewer patients were in
the long-acting insulin group (11.4 %; N = 244) or the
pre-mixed insulin group (5.5 %; N= 118). Among those
receiving an intensive regimen, four types of insulin
combinations were identified (Fig. 2). Almost all patients
(96.7 %; N = 760) in the intensive regimen group used
rapid-acting insulin as a part of a combination therapy
with long-acting and/or pre-mixed insulin.
Patient characteristics
The population characteristics for patients who initiated
insulin are summarized by insulin group in Table 1.
Patients in the rapid-acting insulin group were the old-
est, with a mean age of 72.0 years (SD, 11.2 years),
compared with those receiving other types of insulin,
with means ranging from 65.2 to 66.7 years. More than
half of the patients were male in all insulin groups.
Patients receiving rapid-acting insulin had the lowest
HbA1c (7.4 %)2 [11], and those receiving long-acting in-
sulin had the highest HbA1c (9.4 %)3 [11].
Nearly all patients (92.2 %; N= 225) in the long-acting
insulin group and the majority of patients in each group
(71.2 % [N = 84], 75.4 % [N = 752], and 79.3 % [N= 623]
for the pre-mixed insulin, rapid-acting insulin, or inten-
sive regimen group, respectively) received at least one
oral antidiabetic drug (OAD) or exenatide (injectable)
prior to insulin initiation. The most commonly used
OAD across all insulin initiators was sulfonylureas (SU),
followed by dipeptidyl peptidase-4 (DPP-4) inhibitors
and alpha glucosidase inhibitors.
Comorbid conditions are summarized in Table 2.
Overall, fewer comorbid conditions were observed in the
long-acting insulin group compared with the other
groups. Less than half of all insulin initiators were diag-
nosed with hypertension (40.6 %; N = 870) and approxi-
mately one quarter were diagnosed with nephropathy
(26.6 %; N = 571).
Insulin utilization patterns
As seen in Fig. 2, most intensive regimens combined rapid-
acting insulin and/or other insulin types; the majority of in-
sulin initiators (81.9 %; N= 1,757) used rapid-acting insulin.
Nearly all patients receiving rapid-acting insulin
(91.0 %; N = 907) and the majority of patients receiv-
ing an intensive regimen (72.9 %; N = 573) initiated
insulin in an inpatient setting. Conversely, those pa-
tients receiving long-acting and pre-mixed insulin
Fig. 2 Distribution of insulin regimen type at initiation
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Table 1 Population demographic and clinical characteristics (N = 2,145)
Baseline Patient Characteristic
(N = 2,145)
Long-acting Pre-mixed Rapid-acting Intensive
(N = 244) (N = 118) (N = 997) (N = 786)
Age (years)
Mean (±SD) 65.2 (±12.3) 66.3 (±12.9) 72.0 (±11.2) 66.7 (±12.3)
Range 23-95 24-98 22-105 19-95
Gender, n (%)
Male 158 (64.8) 78 (66.1) 609 (61.1) 477 (60.7)
HbA1c (%)a
Mean 9.4 8.0 7.4 9.1
Median 9.2 7.8 7.0 9.1
Treatment initiation setting, n (%)
Inpatient 40 (16.4) 47 (39.8) 907 (91.0) 573 (72.9)
Outpatient 204 (83.6) 71 (60.2) 90 (9.0) 213 (27.1)
Pre-index antidiabetic medication (OAD), n (%)
Yes 225 (92.2) 84 (71.2) 752 (75.4) 623 (79.3)
DPP-4 inhibitors 127 (52.0) 38 (32.2) 419 (42.0) 316 (40.2)
Alpha glucosidase inhibitors 143 (58.6) 47 (39.8) 374 (37.5) 309 (39.3)
Biguanide 128 (52.5) 30 (25.4) 232 (23.3) 261 (33.2)
Gurinido 40 (16.4) 9 (7.6) 147 (14.7) 128 (16.3)
SU 187 (76.6) 47 (39.8) 507 (50.9) 427 (54.3)
TZD 106 (43.4) 22 (18.6) 179 (18.0) 169 (21.5)
Single-pill combination 10 (4.1) - 8 (0.8) 5 (0.6)
aHbA1c was available only for those with HbAc1 measurement data
aHbA1c was reported with the Japan Diabetes Society (JDS) system in the database; all HbA1c values in this study were converted to the National
Glycohemoglobin Standardization Program (NGSP) system with the formula recommended by JDS (NGSP = JDS + 0.4 [11])
SD, standard deviation; DPP-4, dipeptidyl peptidase-4 inhibitors; SU, sulfonylureas; TZD, thiazolidinediones
Table 2 Patient comorbid conditions (N = 2,145)
Comorbid Condition (N = 2,145) Overall (N = 2,145) Long-acting (N = 244) Pre-mixed (N = 118) Rapid-acting (N = 997) Intensive (N = 786)
Comorbid conditions, n (%)
Hypertension 870 (40.6) 40 (16.4) 42 (35.6) 475 (47.6) 313 (39.8)
Nephropathy 571 (26.6) 31 (12.7) 39 (33.1) 301 (30.2) 200 (25.4)
Ischemic heart disease 398 (18.6) 28 (11.5) 18 (15.3) 212 (21.3) 140 (17.8)
Heart failure 331 (15.4) 15 (6.1) 12 (10.2) 200 (20.1) 104 (13.2)
Cerebrovascular disease 300 (14.0) 9 (3.7) 11 (9.3) 172 (17.3) 108 (13.7)
Neuropathy 189 (8.8) 13 (5.3) 7 (5.9) 100 (10.0) 69 (8.8)
Arthropathy 171 (8.0) 8 (3.3) - 109 (10.9) 54 (6.9)
Depression 59 (2.8) 2 (0.8) - 36 (3.6) 21 (2.7)
Peripheral vascular disease 54 (2.5) 5 (2.0) 1 (0.8) 26 (2.6) 22 (2.8)
Skin complications 37 (1.7) 1 (0.4) 2 (1.7) 15 (1.5) 19 (2.4)
Retinopathy 34 (1.6) 1 (0.4) 1 (0.8) 15 (1.5) 17 (2.2)
Myocardial infarction 28 (1.3) 1 (0.4) 2 (1.7) 12 (1.2) 13 (1.7)
Hypoglycemia 25 (1.2) - - 18 (1.8) 7 (0.9)
Hyperglycemia 12 (0.6) 1 (0.4) - 7 (0.7) 4 (0.5)
Ketoacidosis 7 (0.3) - - 7 (0.9)
Oral complications 1 (0.0) - - 1 (0.1) -
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(83.6 % and 60.2 %, respectively) initiated at an out-
patient setting (Table 1).
Table 3 describes insulin utilization patterns among insu-
lin initiators during their first year of insulin treatment.
More than half of patients receiving long-acting insulin
(63.5 %; N= 155) and pre-mixed insulin (55.1 %; N= 65), as
well as nearly half of patients receiving an intensive regimen
(42.9 %; N= 337), were using insulin consistently for at least
1 year after insulin initiation. Almost all patients receiving
rapid-acting insulin (94.4 %; N= 941) used insulin intermit-
tently or stopped using insulin within 1 year (defined as at
least 100 days between two insulin claims or between the
last one and the end of the observation period). When used
intermittently, insulin was used for a few months, on aver-
age, with a shorter median duration of insulin use for those
receiving pre-mixed insulin (72 days) and rapid-acting insu-
lin (71 days) and a longer median duration of insulin use
for those receiving long-acting insulin (154 days) and an in-
tensive regimen (107 days).
Table 4 describes the insulin treatment modification pat-
terns over the 1-year post-index period based on claims in
their first month. Less than half of patients who were pre-
scribed one type of insulin on their first insulin claim
modified their insulin regimen by switching or adding a
different type of insulin at least once over the 1-year post-
index period (37.7 %, 44.7 %, and 34.0 % for long-acting,
pre-mixed, and rapid-acting insulin, respectively). The
median number of days for modification of the initial
treatment after the date they received their first insulin
claim was 86, 28, and 17 days for long-acting, pre-mixed,
and rapid-acting insulin, respectively. On the other hand,
the majority (84.4 %; N= 184) of patients who had mul-
tiple types of insulin on their first insulin claim modified
their insulin regimen after a median of 15 days. One pa-
tient had a record for unspecified type of insulin on the
first insulin claim; therefore, this patient was excluded
from the treatment modification analysis only.
Healthcare service utilization
Data on healthcare service utilization are summarized in
Table 5. Nearly all patients receiving rapid-acting insulin
(95.5 %; N = 952) and the majority of patients receiving
an intensive regimen (87.9 %; N = 691) were hospitalized
at some point during the first year of insulin treatment,
whereas only half of (55.1 %; N = 65) and one third of
patients (32.8 %; N = 80) receiving pre-mixed and long-
acting insulin, respectively, were hospitalized. Patients in
the long-acting group had fewer and shorter hospitaliza-
tions than other groups during the 1-year post-index
period, with a median of one hospitalization for approxi-
mately two weeks. Patients receiving rapid-acting insulin
or an intensive regimen spent more days in the hospital
(a median of 18.8 and 21.0 days, respectively) than those
in the long-acting and pre-mixed insulin groups
(Table 5).
The majority of the rapid-acting (78.5 %; N= 747) and
the intensive regimen groups (71.9 %; N= 497) were also
rehospitalized during their first year on insulin treat-
ment; fewer patients taking long-acting or pre-mixed
therapy were rehospitalized (47.5 % and 56.9 %, respect-
ively). Median days between hospitalizations were lon-
gest for those taking pre-mixed insulin (159.5 days);
other treatment groups had shorter times with a median
of 63.5, 87.0, and 80.0 days for the long-acting, rapid-
acting, and intensive regimens, respectively. All groups
visited an outpatient clinic approximately once per
month (median of 14-16 times per year). Emergency de-
partment visits were observed to be rare, with almost no
visit to the emergency department across all groups
(Table 5).
Discussion
The primary objective of this study was to describe and
evaluate real-world treatment patterns and healthcare
service utilization among patients with T2DM in Japan
over the 1-year period following initiation of insulin
therapy. Few reports describing treatment practice pat-
terns in insulin use among initiators, and via these
methods, are available. Although previous studies have
investigated the trends in antidiabetic prescription pat-
terns [12, 13], no study has examined different insulin
regimens or evaluated healthcare service utilization
Table 3 Insulin utilization patterns by insulin type (N = 2,145)
Insulin Use (N = 2,145) Long-acting (N = 244) Pre-mixed (N = 118) Rapid-acting (N = 997) Intensive (N = 786)
Used consistentlya, n (%) 155 (63.5) 65 (55.1) 56 (5.6) 337 (42.9)
Used intermittingly or dropped outb, n (%) 89 (36.5) 53 (44.9) 941 (94.4) 449 (57.1)
Duration of insulin use, days
Mean (±SD) 150.7 (±108.7) 121.8 (±112.8) 108.1 (±104.5) 132.1 (±102.1)
Median 154.0 72.0 71.0 107.0
a Patients did not have more than 100 days between two adjacent insulin treatments or more than 100 days between the last insulin treatment and the end of
the 1-year post-index period
b Patients had more than 100 days between two adjacent insulin treatments or more than 100 days between the last insulin treatment and the end of the 1-year
post-index period
SD, standard deviation
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Table 4 Insulin treatment modification by initial insulin type from first claim (N = 2,145)
Insulin type prescribed on the first claim
Long-acting insulin only Pre-mixed insulin only Rapid-acting insulin only Intensive insulin Unspecified insulin
N (%) 363 (16.9) 190 (8.9) 1373 (64.0) 218 (10.2) 1 (0.0)
Switched or added an insulin type at least once over the 1-year period, n (%) 137 (37.7) 85 (44.7) 467 (34.0) 184 (84.4) NA
Days between index and first insulin switch or additiona
Mean (±SD) 119.0 (±118.7) 91.1 (±113.2) 71.5 (±100.7) 54.3 (±82.1) NA
Median 86 28 17 15 NA
aOnly patients with at least one insulin type switch over the 1-year index period were included
SD, standard deviation; NA, Not applicable
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among those regimen groups. Similarly designed data-
base studies have thus far focused on other patient pop-
ulations [10] or were conducted in other regions [13].
Nonetheless, automated health resource databases, such
as the MDV database, have been found to provide valid
and reliable data for pharmacoepidemiologic studies of
various diseases [14].
The current study found that the most commonly
used insulin therapy among insulin initiators in the
database was rapid-acting insulin alone followed by
an intensive treatment regimen, which included four
different variations of complex regimens. Although
the use of long-acting insulin and pre-mixed insulin
alone was not frequently observed, most of these pa-
tients were taking at least one OAD prior to insulin
initiation, thus likely using insulin as a supplement to
their antidiabetic therapy. This is consistent with the
literature [9]. The higher proportion of rapid-acting
insulin compared to long-acting insulin was consistent
with the findings of the Cardiovascular Risk Evalu-
ation in people with type 2 Diabetes on Insulin Ther-
apy (CREDIT) study and appeared unique to Japan,
as long-acting insulin was observed to be most com-
monly used as the first insulin in other regions [15].
Moreover, it has been reported that although the
overall use of pre-mixed insulin has decreased, the
administration of an intensive regimen with rapid-
acting and long-acting insulin, as well as bolus
(mealtime) therapy using rapid-acting insulin alone,
have recently increased [7].
The patient profile of the long-acting and pre-mixed
groups appeared to be similar, but the other two groups
were different in terms of age and comorbid conditions.
Such disparities in patient characteristics among differ-
ent insulin regimens have been observed previously [12],
and a previous study of insulin use patterns among insu-
lin initiators excluded patients using rapid-acting and an
intensive regimen to achieve a more homogeneous pa-
tient population [13]. Our finding of insulin initiation in
an inpatient setting being observed more frequently
among those receiving an intensive regimen or rapid-
acting insulin may reflect their disease profile being
more complicated and requiring specialized care. Previ-
ously, initiating insulin as an inpatient was reported
among 63.6 % of patients with T2DM regardless of insu-
lin type [16].
The disparities in patient characteristics may also be
reflected in our finding of insulin therapy modification.
Our finding of insulin modification patterns for patients
who received a single type of insulin on their first insulin
claim was consistent with the previous studies in other
countries which reported modification rates ranging
from 5 % [16] over one year to 43.4 % [17] over five
years. However, patients who received multiple types of
insulin on their first insulin index were more likely to
modify their therapy regimen compared with those who
Table 5 Healthcare service utilization (N = 2,145)
Healthcare Service (N = 2,145) Long-acting (N = 244) Pre-mixed (N = 118) Rapid-acting (N = 997) Intensive (N = 786)
Hospitalization
Patients hospitalized during the first year, n (%) 80 (32.8) 65 (55.1) 952 (95.5) 691 (87.9)
N of hospitalizations per patient
Mean (±SD) 2.2 (±1.9) 2.1 (±1.5) 2.7 (±1.9) 2.4 (±1.6)
Median 1.0 2.0 2.0 2.0
Length of stay, days
Mean (±SD) 20.8 (±27.8) 20.7 (±20.9) 28.0 (±29.2) 27.3 (±23.8)
Median 14.3 16.0 18.8 21.0
Patients re-hospitalized, n (%) 38 (47.5) 37 (56.9) 747 (78.5) 497 (71.9)
Days between two hospitalizations
Mean (±SD) 103.8 (±101.7) 161.8 (±97.4) 109.3 (±83.9) 104.1 (±82.7)
Median 63.5 159.5 87.0 80.0
Outpatient visits
Mean (±SD) 20.4 (±25.7) 26.1 (±40.4) 19.9 (±23.5) 22.5 (±26.3)
Median 14.0 13.5 15.0 16.0
Emergency room visits
Number of visits (all patients)
Mean (±SD) 0.0 (±0.0) 0.0 (±0.2) 0.0 (±0.2) 0.1 (±0.6)
Median 0.0 0.0 0.0 0.0
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received a single type of insulin on the first claim. Be-
cause these patients with multiple types of insulin on the
first insulin claim belonged to the intensive regimen
group (who mostly initiated insulin at an inpatient set-
ting), it is possible that they received closer monitoring
and hence were able to switch or add different insulin
within a shorter time period.
It is notable that the majority of patients (nearly half
of patients receiving an intensive regimen and almost all
patients receiving rapid-acting insulin) had a 100-day
gap between two insulin claims. This finding was con-
sistent with prior research. An analysis of long-acting
and pre-mixed insulin use patterns in the United States
found that the majority of insulin initiators (73.5 % tak-
ing long-acting insulin and 64.0 % taking pre-mixed in-
sulin) had a 90-day gap between adjacent insulin
prescriptions in their first year and were not using insu-
lin “persistently” [13]. Another retrospective database
analysis reported that 37.0 % of insulin initiators were
not persistent with insulin therapy at 12 months follow-
up [18]. However, in the former study, it was reported
that almost all (more than 80 %) of those with a 90-day
gap restarted insulin after approximately 140 days [13].
Therefore, patients considered “dropped out” from insu-
lin therapy due to our 100-day gap definition in the
current study might indeed restart insulin. Nevertheless,
more patients appeared to be able to stop insulin ther-
apy when they received rapid-acting insulin or an inten-
sive regimen based on our findings for insulin
discontinuation and intermittent use; therefore, although
some patient characteristics differed among groups, it is
possible that intensive regimens were more effective in
relieving glucose toxicity.
Although efforts were made to avoid potential bias as-
sociated with only acute-phase treatment by excluding
patients who did not continue insulin after discharge
from the analyses, it is possible that insulin, especially
rapid-acting and regular insulin, which can easily control
glucose level, was used for a short period of time in the
case of significantly elevated blood glucose during acute-
phase treatment of a primary disease or surgery [6, 19].
Such a diverse role of rapid-acting insulin at both spe-
cialized and nonspecialized settings has been previously
reported [8]. The hospitals included in this analysis were
mainly medium or large acute-phase hospitals with spe-
cialized physicians, and patients receiving rapid-acting
insulin or an intensive regimen were observed to have
more complications, likely requiring specialized care. In
addition, given the length of hospital stay observed in
the current study, it is possible that patients received
rapid-acting insulin alone or as a part of an intensive
regimen for educational/training purposes. Local guide-
lines recommend some patients initiate insulin therapy
in-hospital and stay for approximately 7 to 14 days to
acclimate to the new insulin regimen [6], and an inten-
sive regimen has been proven effective among those ini-
tiating insulin through this educational hospitalization
program [20].
Although enabling the powerful and relatively efficient
evaluation of large swaths of healthcare data, the
methods of the current study were not without their
limitations. First, the database examined did not allow
for the linkage of diagnosis and prescription data dir-
ectly; therefore, it was difficult to ensure patients’
utilization of insulin was truly for diabetes rather than
glucose toxicity [19]. Second, due to the nature of ad-
ministrative hospital-based databases, the database only
reflected medium- and large-sized administrative hospi-
tals and did not include outpatient clinics. It was also
not possible to follow those patients who went to a dif-
ferent hospital or clinic or to identify the same patient
receiving care at more than one hospital. This reduced
the generalizability of the data because the data collected
were restricted to reflect clinical practice at larger hos-
pital settings and patients who returned to the same
hospital or clinic for continuous care. Third, the sample
size was relatively small after only including patients
with three insulin claims and excluding those patients
who did not continue taking insulin after hospitalization.
However, these restrictions were important, providing
more confidence that the population analyzed was truly
diabetic and not simply receiving insulin for other rea-
sons. Fourth, treatment patterns of insulin initiators
were complicated; therefore, it is possible that classifying
insulin regimen group based on claims over the year re-
sulted in misclassification for some cases. As seen in our
modification analysis, three of the groups added or
changed treatment within a median of 30 days. There-
fore, it is possible that they were misclassified into a
more intensive treatment regimen when they only
switched to a different class of therapy. Additionally, in-
sulin daily dose is not reliable because total volume is
provided but the duration is not; therefore, the time be-
tween prescriptions was used as a proxy for monthly or
3-month prescriptions. Finally, the database did not pro-
vide key clinical information that would determine
clinical decision making on types of insulin regimen
such as body mass index (BMI), duration of disease,
hypoglycemia inpatient admission, or useful days supply
for insulin prescriptions. The patient profile across
groups may have differed due to these unobserved fac-
tors or information unavailable in the database. For ex-
ample, previous studies have reported that age at
diagnosis, disease duration, and BMI were associated
with clinical outcomes [7, 21] and that disease duration
and daily insulin dosage at the initiation were associated
with insulin discontinuation [22]. We recommend care-
ful interpretation of the current findings.
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Conclusions
This is the first multi-center retrospective database study
to delineate the real-world insulin utilization patterns
and healthcare service use among all types of insulin ini-
tiators with T2DM in Japan. Variation in patient charac-
teristics and insulin utilization patterns across insulin
groups were revealed, particularly between the long-
acting/pre-mixed groups and the rapid-acting/intensive
regimen groups, in terms of age and comorbid condi-
tions. Healthcare services were found to both diverge
(e.g., hospitalization) and remain similar (e.g., emergency
department visits) among the groups. Although add-
itional research to further delineate the factors influen-
cing insulin use and regimen initiation remains
warranted, the current study provides valuable insight
into the real-world insulin and healthcare service
utilization patterns in Japan. Future research should as-
sess the basis for these various utilization patterns asso-
ciated with insulin to conduct robust analyses of clinical
and economic outcomes. The detailed treatment pat-
terns and healthcare service use by insulin regimen pro-
vides a foundation for future research to build upon.
Endnotes
1Excludes those living in the areas severely affected by
the 2011 Great East Japan Earthquake.
27.4 % HbA1c was calculated based on 7.0 % JDS
39.4 % HbA1c was calculated based on 9.0 % JDS
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